<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">EMLA (EUTECTIC MIXTURE OF LIDOCAINE AND PRILOCAINE)</span><br/><span class="topboxtradename">EMLA Cream<br/></span><b>Classifications:</b> <span class="classification">central nervous system agent</span>; <span class="classification">local anesthetic</span><br/><b>Prototype: </b>Procaine<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>2.5% lidocaine/2.5% prilocaine cream</p>
<h1><a name="action">Actions</a></h1>
<p>EMLA cream is a mixture of lidocaine and prilocaine. The mixture forms a liquid at room temperature. Concentration of anesthetic
         in liquid versus an emulsifier is 80% versus 20%.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>EMLA is a topical analgesic.</p>
<h1><a name="uses">Uses</a></h1>
<p>Topical anesthetic on normal intact skin for local anesthesia.</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Topical anesthetic prior to leg ulcer debridement; treatment of postherpetic neuralgia.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Patients with known sensitivity to local anesthetics; patients with congenital or idiopathy methemoglobinemia.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Acutely ill, debilitated, or older adult patients; severe liver disease; pregnancy (category B), lactation; children 
      </p><h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Topical Anesthetic</span><br/><span class="rdage">Adult/</span><span class="rdage">Child:</span> <span class="rdroute">Topical</span>
<i>&gt;1 mo,</i> Apply 2.5 g of cream (½ of 5-g tube) over 2025 cm<sup>2</sup> of skin, cover with occlusive dressing and wait at least 1 h, then remove dressing and wipe off cream, cleanse area with
               an antiseptic solution and prepare patient for the procedure<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Topical</span><br/><ul>
<li>Apply a thick layer to skin (approximately ½ of 5-g tube per 2025 cm<sup>2</sup> or 2 <small>x</small> 2 in) at site of procedure. Apply an occlusive dressing. Do not spread out cream. Seal edges of dressing
            well to avoid leakage.
         </li>
<li>Apply EMLA cream 1 h before routine procedure and 2 h before painful procedure.</li>
<li>Remove EMLA cream prior to skin puncture and clean area with an aseptic solution.</li>
<li>Store at room temperature 15°30° C (59°86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Hematologic:</span> Methemoglobinemia, especially in infants, small children, and patients with G6PD deficiency. <span class="typehead">Skin:</span>
<span class="speceff-common">Blanching and redness,</span> itching, heat sensation. <span class="typehead">Body as a Whole:</span>  Edema, soreness, aching, numbness, heaviness. <span class="typehead">Other:</span> The adverse effects of lidocaine could occur with large doses or if there is significant systemic absorption. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead"> Drug:</span>  May cause additive toxicity with <span class="classification">class i antiarrhythmics</span>; may increase risk of developing methemoglobin when used with <b>acetaminophen,</b>
<b>chloroquine,</b>
<b>dapsone,</b>
<b>fosphenytoin,</b>
<span class="classification">nitrates</span> and <span class="classification">nitrites</span>, <b>nitric oxide,</b>
<b>nitrofurantoin,</b>
<b>nitroprusside,</b>
<b>pamaquine,</b>
<b>phenobarbital,</b>
<b>phenytoin,</b>
<b>primaquine,</b>
<b>quinine,</b> or <span class="classification">sulfonamides</span>. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Penetrates intact skin. <span class="typehead">Onset:</span> 1560 min. <span class="typehead">Peak:</span> 23 h. <span class="typehead">Duration:</span> 12 h after removal of cream. <span class="typehead">Distribution:</span> Crosses bloodbrain barrier and placenta, distributed into breast milk. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> 98% of absorbed dose is excreted in urine. <span class="typehead">Half-Life:</span> 60150 min. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for local skin reactions including erythema, edema, itching, abnormal temperature sensations, and rash. These reactions
            are very common and usually disappear in 12 h.
         </li>
<li>
            							Note: Patients taking Class 1 antiarrhythmic drugs may experience toxic effects on the cardiovascular system. EMLA should be used
            with caution in these patients.
            						
         </li>
<li>Wash immediately with water or saline if contact with the eye occurs; protect the eye until sensation returns.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Skin analgesia lasts for 1 h following removal of the occlusive dressing. Analgesia may be accompanied by temporary loss of
            all sensation in the treated skin. Advise caution until sensation returns.
         </li>
<li>Do not breast feed while using this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>